Tubulis Introduces Novel Platform Approach for Accelerated ADC Development at the 9th World ADC London 2019

--Data demonstrate platform feasibility to rapidly generate novel ADC combinations with superior stability--

MARTINSRIED, GERMANY, March 6, 2019 – Tubulis today announced pre-clinical data evaluating its sophisticated dual platform for the rapid screening and production of highly stable and efficient antibody-drug conjugates (ADCs). The results highlight the technology’s ability to create a wide variety of ADCs with superior plasma stability and the potential for higher efficacy by overcoming limitations that have inhibited the success of many ADCs to-date. The data were presented by Tubulis Co-founder and Chief Scientific Officer Dr. Jonas Helma-Smets in an oral presentation at the 9^th World ADC London.

“Tubulis was established to address existing shortcomings in the ADC field and the results we presented at the ADC World showcase that our novel strategy offers a unique potential to overcome the current limitations of stability and payload-protein combinations,” said Jonas Helma-Smets, CSO and Co-founder of Tubulis. “We believe that our combined platform approach will enable us to broaden the therapeutic applications of ADCs into other disease indications beyond cancer. Our near-term goal is to build a solid foundation for us as a newly established company in order to further advance our promising technology.”

In the presentation, Tubulis demonstrated in cell culture and mouse tumor studies that its novel proprietary ADC development approach rapidly produces ADC candidates with equal or superior efficacy compared to established linker technologies. The candidates furthermore show antibody-like stability in classical in vitro assays as well as indicate the potential to reduce the dosing regimen due to improved payload delivery in in vivo models. Overall, these results underline that Tubulis’ unique technology combination provides an excellent enzymatic platform for the accelerated development of chemically flexible and highly stable ADCs at lower costs.

Tubulis’ proprietary dual ADC development approach is based on an initial screening platform with fast conjugation (P5) to rapidly identify novel protein-drug combinations for therapeutic application. P5 is a cysteine-based conjugation method that shows an increased reaction selectivity and high chemical flexibility, enabling the fast and efficient conjugation of any antibody to any payload. The selected best combinations are then advanced via the Tub-tag conjugation technology to create uniquely stable therapeutic candidates. The Tub-tag, a short protein (α-tubulin) sequence fused to the protein of interest, uses aspects of microtubule biology to introduce a highly beneficial microenvironment for payload conjugation, thereby broadening the spectrum of currently possible protein-drug combinations.

About Tubulis

Tubulis Technologies generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.

Contacts